SCHEMBL1665148

SCHEMBL1665148

CN(C)C(=O)Oc1cc(F)c(C=O)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.50
ACHE P22303 8/20 0.41
LMNA P02545 6/20 0.41
BCHE P06276 5/20 0.41
GLA P06280 2/20 0.41
NCEH1 Q6PIU2 2/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.39
CYP2D6 P10635 2/20 0.38
ADRB2 P07550 1/20 0.38
KCNH2 Q12809 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665868 0.77 LMNA (0.38) LMNAGAAALDH1A1PKM
SCHEMBL28332668 0.77 MEN1 (0.44) LMNAKMT2AMEN1
SCHEMBL28972926 0.76 CA2 (0.37) LMNAKMT2AMEN1
SCHEMBL26424691 0.76 RAB9A (0.50) RAB9AACHELMNABCHENCEH1
SCHEMBL1665879 0.73 MMP2 (0.36) LMNAGLA
SCHEMBL1667775 0.73 KMT2A (0.42) RAB9ALMNAKMT2AMEN1GAA
SCHEMBL1667900 0.72 MAOB (0.46) RAB9AACHEBCHENCEH1TSHR
SCHEMBL954134 0.71 ERN1 (0.50) LMNAALDH1A1PKM
SCHEMBL18058841 0.70 RAB9A (0.61) RAB9AACHELMNABCHEGLA
SCHEMBL10093728 0.70 RAB9A (0.61) RAB9AACHELMNABCHEGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493905-B1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT CO LLC (PR) 2016-11-30 EP disclosed
US-8822435-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-09-02 US disclosed
US-20140194389-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2014-07-10 US disclosed
US-8710215-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-04-29 US disclosed
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2013-02-07 US disclosed
US-8314081-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2012-11-20 US disclosed
EP-2493905-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS Warner Chilcott Company, LLC (PR) 2012-09-05 EP disclosed
WO-2011056589-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT COMPANY, LLC (US) 2011-05-12 WO disclosed
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194389-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN RAB9A 556/4885ACHE 4588/4885LMNA 4003/4885
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN RAB9A 556/4885ACHE 4588/4885LMNA 4003/4885
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN RAB9A 556/4885ACHE 4588/4885LMNA 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.